Therapeutic results of patients with endometriosis and ovarian cancer

Introduction. The aim of this study is to compare the therapeutic results of patients with ovarian cancer coexisting with endometriosis with a group of patients with cancer formed in the endometriosis focus in the scar after caesarean section. Methods. We analysed the therapeutic results of patients with ovarian cancer coexisting with endometriosis with a group of patients with cancer formed in the endometriosis focus in the scar after caesarean section. They were operated in the Oncology Centre in Bydgoszcz. All the patients had endometriosis and ovarian cancer confirmed in one tissue preparation. Results. The probability of death at any time is 7.826-times higher in the group with scar cancer than in the group with endometriosis and ovarian cancer. Conclusions. Because scar cancer that arises in the background of endometriosis is an extremely rare condition and also because the prognosis for this group of patients is poor we consider it necessary to plan combination therapy by a multidisciplinary oncological team.

ovarian cancerendometriosisovarian neoplasms

- Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012; 124(1): 164–169. - Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010; 362(25): 2389–2398. - Ho HN, Wu MY, Yang YS. Peritoneal cellular immunity and endometriosis. Am J Reprod Immunol. 1997; 38: 400–412. - Montgomery GW, Nyholt DR, Zhao ZZ, et al. The search for genes contributing to endometriosis risk. Hum Reprod Update. 2008; 14(5): 447–457. - Daraï E, Detchev R, Hugol D, et al. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours. Hum Reprod. 2003; 18(8): 1681–1685. - Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674. - Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol. 2007; 213(3): 581–588. - Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255): 539–545. - Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res. 2005; 93: 159–187. - Allavena P, Sica A, Garlanda C, et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008; 222: 155–161. - Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunology Today. 1992; 13(7): 265–270. - Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4(1): 71–78. - Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006; 25(3): 315–322. - Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000; 11(2): 111–117. - Nezhat F, Datta MS, Hanson V, et al. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008; 90(5): 1559–1570. - Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 2007; 130(3): 440–455. - Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 2004; 6(3): 297–305. - Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441(7092): 431–436.